AstraZeneca COVID-19 Antibody Could Be Solution For Vulnerable But Not Vaccine Alternative

Long-Acting Drug Filed With FDA

 
• By Andrew McConaghie
  
Astrazeneca
AstraZeneca's antibody therapy could be first to gain an EUA in 'pre-exposure prophylaxis'

More from COVID-19

More from Scrip